Active, not recruitingPhase 2NCT06230354
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
Studying Eosinophilic granulomatosis with polyangiitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Imperial College London
- Principal Investigator
- Salman Siddiqui, MBBSImperial College London
- Intervention
- Tezepelumab(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2025
Study locations (13)
- Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, United Kingdom
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
- Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
- Barts Health NHS Trust, London, United Kingdom
- Royal Free London NHS Trust, London, United Kingdom
- Guy's Hospital - Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
- Royal Brompton Hospital - Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
- Imperial College Healthcare NHS Trust, London, United Kingdom
- Manchester University NHS Foundation Trust, Manchester, United Kingdom
- Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom
- University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Collaborators
AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06230354 on ClinicalTrials.govOther trials for Eosinophilic granulomatosis with polyangiitis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE4NCT07343661Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPAAzienda Ospedaliero Universitaria di Cagliari
- RECRUITINGPHASE3NCT06512883A Trial to Investigate Benralizumab in Children With Eosinophilic DiseasesAstraZeneca
- RECRUITINGNCT06298448eGPA and Local Inflammation Within the Ear, Nose and Throat AreaUniversity Medical Center Groningen
- RECRUITINGPHASE2NCT06046222Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With PolyangiitisNS Pharma, Inc.
- RECRUITINGPHASE2, PHASE3NCT05979051A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）Guangdong Hengrui Pharmaceutical Co., Ltd
- ACTIVE NOT RECRUITINGPHASE3NCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)GlaxoSmithKline
- ACTIVE NOT RECRUITINGPHASE3NCT05030155Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)Assistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT02947945Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) StudyNational Jewish Health
See all trials for Eosinophilic granulomatosis with polyangiitis →